Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study

Publication date: Available online 1 March 2018 Source:The Lancet Psychiatry Author(s): Hao Yu, Hao Yan, Lifang Wang, Jun Li, Liwen Tan, Wei Deng, Qi Chen, Guigang Yang, Fuquan Zhang, Tianlan Lu, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xiao Xiao, Ming Li, Xin Ma, Fude Yang, Lingjiang Li, Chuanyue Wang, Tao Li, Dai Zhang, Weihua Yue Background Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. Methods The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p<1 × 10−5) were tested in a va...
Source: The Lancet Psychiatry - Category: Psychiatry Source Type: research

Related Links:

Authors: Citrome L, Zeni CM, Correll CU Abstract Transdermal delivery is an alternative to oral routes of drug administration and has made considerable contributions to the treatment of various medical diseases. With the advent of new transdermal delivery technologies, higher numbers of medications are being approved for use as transdermal formulations. This route of administration has several innate advantages that have the potential to benefit various patient populations, including those with central nervous system disorders. The current review briefly outlines the history of transdermal medications, discusses th...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
In conclusion, SCZOff showed neurocognitive impairments in several neuropsychological domains compared to CCOff. Neuropsychological functioning, environmental factors and positive prodromal symptoms could predict the risk of onset of severe mental disorders in SCZOff. PMID: 31312885 [PubMed - as supplied by publisher]
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research
Condition:   Schizophrenia Intervention:   Device: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System Sponsors:   ERP Biomarker Qualification Consortium;   COGNISION;   Cadent Therapeutics;   Alkermes, Inc.;   Anavex Life Sciences Corp.;   Merck Sharp & Dohme Corp.;   Takeda;   Sage Therapeutics;   H. Lundbeck A/S Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Schizophrenia Interventions:   Behavioral: Social Cognition Training;   Behavioral: Informations Sponsor:   Hôpital le Vinatier Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Choosing the best antipsychotic for individual patients with schizophrenia is challenging. A new meta-analysis seeks to inform that choice by ranking 32 antipsychotics on the basis of efficacy and safety.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Psychiatry News Source Type: news
Publication date: Available online 19 July 2019Source: Brain, Behavior, and ImmunityAuthor(s): Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, Jeremy S. Lum, Xu-Feng Huang, Kelly A. Newell, Katrina Weston-GreenAbstractCognitive impairment is a major source of disability in schizophrenia and current antipsychotic drugs (APDs) have minimal efficacy for this symptom domain. Cannabidiol (CBD), the major non-intoxicating component of Cannabis sativa L., exhibits antipsychotic and neuroprotective properties. We recently reported the effects of CBD on cognition in male offspring of a maternal immune activation (polyinosinic-po...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
(Emory Health Sciences) 3q29 deletion syndrome is a strong risk factor for both schizophrenia and autism spectrum disorder. People with the rare condition have a distinct neuropsychiatric profile, researchers found.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Condition:   Metabolic Syndrome Interventions:   Other: Dietary Approaches to Stop Hypertension;   Other: Nutrition education program Sponsors:   Tamara Sorić;   University of Zagreb Completed
Source: - Category: Research Source Type: clinical trials
Conditions:   Schizophrenia;   Depression;   Motivation;   Anhedonia, Physical;   Anhedonia, Social;   Negative Symptoms With Primary Psychotic Disorder Interventions:   Behavioral: Self-rating Questionnaires;   Behavioral: Measures of Reward processing/reinforcement learning;   Behavioral: Additional Schizophrenia-specific Questionnaires and Interviews Sponsors:   Maastricht University;   P1vital Products LTD.;   BIOTRIAL;   University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medi...
Source: - Category: Research Source Type: clinical trials
More News: Abilify | Brain | China Health | Funding | Genetics | Geodon | Hospitals | Neurology | Neuroscience | Psychiatry | Risperdal Consta | Schizophrenia | Science | Seroquel | Study | Ziprasidone | Zyprexa